We are not currently accepting registrations for this pre-pilot programme. We will however be issuing a survey imminently inviting participants to register an interest for the next trial issue which we hope to send later in 2018. In this study, a cell line or patient sample will be issued alongside a clinical scenario. Participants will be expected to test the sample with their in-house strategy for testing MPNs. The programme primarily focusses on JAK2 (V617F and exon 12), CALR and MPL mutations (Tefferi & Pardanani, 2014). However results from broader panels are accepted.